Novavax’s COVID-19 vaccine, Nuvaxovid, has been authorised for use in the UK for those aged 18 and over. Prof. Paul Heath (St George’s, University of London, London, UK) kindly met with touchINFECTIOUS DISEASES to discuss the Novavax vaccine (Nuvaxovid), the clinical evidence in support of its use and the impact on the COVID-19 vaccination program in the UK.
More information on the phase 3 Novavax results, and the program of clinical trials across the US, South Africa and UK can be accessed below:
- Phase 3 results – Novavax investigational COVID-19 vaccine
- Novavax phase 3 program of clinical trials evaluating NVX-CoV2373 across the US, South Africa and UK
Question:
- Could you give us a brief overview of the Novavax vaccine, the clinical evidence in support of its use and the impact of the vaccine on the COVID-19 vaccination program in the UK?
Disclosures: Paul Heath has received grant/research support from Novavax, Pfizer, AstraZeneca, Valneva, and Moderna.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
